International Stem Cell Corporation (ISCO)

Market Cap	1.66M
Revenue (ttm)	7.59M
Net Income (ttm)	-705,000
Shares Out	8.00M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31
Open	0.190
Previous Close	0.190
Day's Range	0.190 - 0.190
52-Week Range	0.110 - 0.540
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About ISCO

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in North America, Asia, Europe, and internationally. The company's products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson's disease and other central nervous system disorders; and develops, manufactures, and markets anti-aging skincare and human cell culture products. T...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 26
• Stock Exchange: OTCMKTS
• Ticker Symbol: ISCO

Financial Performance

In 2021, ISCO's revenue was $7.18 million, an increase of 0.67% compared to the previous year's $7.13 million. Losses were -$899,000, -67.00% less than in 2020.